Immune checkpoint inhibitors (ICIs) targeting programmed death-1 (PD-1) or cytotoxic T lymphocyte antigen-4 (CTLA-4) are widely used to treat advanced solid cancers, including HCC (9). Here, CTLA4 is linked to hepatocellular carcinoma.